Mobile Site ›

Paroxysmal Nocturnal Hemoglobinuria



Subscribe

Receive notification when new Hot Topics are published:

New Developments

Slide 7

December 2010

Two recent discoveries have changed PNH practice. First, a therapeutic antibody Eculizumab, which is directed against complement has been developed for clinical use, resulting in less requirements for transfusion and improved life quality. Importantly, for the clinical practice, the use of antibody is associated with less complications, but the percentage of PNH cells often increases due to inhibition of lysis.

New Developments

 


Jump to section:


Key